Our top pick for
Kymera Therapeutics, Inc is a biotechnology business based in the US. Kymera Therapeutics shares (KYMR) are listed on the NASDAQ and all prices are listed in US Dollars. Kymera Therapeutics employs 64 staff and has a trailing 12-month revenue of around USD$23.1 million.
|52-week range||USD$25.43 - USD$53.49|
|50-day moving average||USD$39.0014|
|200-day moving average||USD$35.2936|
|Wall St. target price||USD$51.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$23.1 million|
|Gross profit TTM||USD$-34,224,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$2.2 billion|
TTM: trailing 12 months
There are currently 461,322 Kymera Therapeutics shares held short by investors – that's known as Kymera Therapeutics's "short interest". This figure is 1.9% down from 470,219 last month.
There are a few different ways that this level of interest in shorting Kymera Therapeutics shares can be evaluated.
Kymera Therapeutics's "short interest ratio" (SIR) is the quantity of Kymera Therapeutics shares currently shorted divided by the average quantity of Kymera Therapeutics shares traded daily (recently around 99853.246753247). Kymera Therapeutics's SIR currently stands at 4.62. In other words for every 100,000 Kymera Therapeutics shares traded daily on the market, roughly 4620 shares are currently held short.
However Kymera Therapeutics's short interest can also be evaluated against the total number of Kymera Therapeutics shares, or, against the total number of tradable Kymera Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kymera Therapeutics's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Kymera Therapeutics shares in existence, roughly 10 shares are currently held short) or 0.0142% of the tradable shares (for every 100,000 tradable Kymera Therapeutics shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kymera Therapeutics.
Find out more about how you can short Kymera Therapeutics stock.
We're not expecting Kymera Therapeutics to pay a dividend over the next 12 months.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.